pharmaceutical
GSK receives positive opinion for triple-therapy inhaler
September 15, 2017Medical Communications, Sales and Marketing GSK, biotech, drugs, pharma, pharmaceutical
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
GDPR and Human Data Samples: Being ‘somewhat prepared’ is not enough
September 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GDPR, biotech, data, drugs, pharma, pharmaceutical
Thomas Hirse, Partner, and Paetrick Sakowski, Associate, CMS, discuss what pharmaceutical companies need to be aware of ahead of the …
FDA panel gives GSK’s Shingrix unanimous approval
September 14, 2017Sales and Marketing GSK, Shingrix, biotech, drugs, pharma, pharmaceutical, shingles
The FDA’s advisory panel has given a strong signal that GSK’s Shingrix should not have too much difficulty getting full …
Novo’s Xultophy beats basal insulin in cutting cardiovascular risk
September 14, 2017Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
‘Pharma bro’ Shkreli heads to jail
September 14, 2017Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
September 14, 2017Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
Sanofi/Regeneron new asthma data bolstered by potential indications
September 13, 2017Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …
Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
September 13, 2017Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
23andMe raises $250m in financing, research points towards its future
September 13, 2017Research and Development, Sales and Marketing 23andME, biotech, drugs, pharma, pharmaceutical
23andMe made two announcements on the same day that point towards the future of its business: it revealed it had …
Recipharm and CTC launch integrated first in human service
September 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm, biotech, drugs, pharma, pharmaceutical
Contract development and manufacturing organisation (CDMO) Recipharm and contract research organisation (CRO) Clinical Trial Consultants (CTC) have partnered to launch …
Newly adopted flu vaccine could save 1,700 lives
September 12, 2017Research and Development, Sales and Marketing biotech, drugs, flu, fluad, pharma, pharmaceutical, seqirus
The Fluad flu vaccine, produced by Seqirus, was approved by the MHRA for use beginning in 2018 and further data …
Teva announces sale of Paragard for $1.1 billion
September 12, 2017Manufacturing and Production, Sales and Marketing Paragard, Teva, biotech, drugs, pharma, pharmaceutical
Shortly after the news that Teva had finally sealed the deal on a new CEO, it also announced that it …
Questions raised after two deaths in AbbVie arthritis study
September 12, 2017Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
